Straits Times Index
3,343.16 +12.35 (+0.37%) Nikkei
38,661.04 -42.47 (-0.11%) Hang Seng
18,376.76 -100.04 (-0.54%) FTSE 100
8,285.34 +38.39 (+0.47%) Bitcoin USD
70,908.44 -265.51 (-0.37%) CMC Crypto 200
1,475.89 -48.91 (-3.21%)
APLS Oct 2024 30.000 call
| Previous close | 21.00 |
| Open | 21.00 |
| Bid | 13.30 |
| Ask | 14.60 |
| Strike | 30.00 |
| Expiry date | 2024-10-18 |
| Day's range | 21.00 - 21.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 5 |
ZacksWhy Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GlobeNewswireApellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
WALTHAM, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 4:00 p.m. ET. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event. Abou
ZacksApellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data
Apellis (APLS) reports positive one-year data from the mid-stage study evaluating systemic pegcetacoplan to treat two rare and debilitating kidney diseases.
